We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
Read MoreHide Full Article
What Does Viking Therapeutics Do?
Viking Therapeutics (VKTX) is a company that develops treatments for metabolic and endocrine disorders. VKTX’s focus is on creating medication to address conditions such as steatohepatitis (NASH), a liver disease, as well as obesity and diabetes. Through its expertise in receptor signaling pathways, Viking Therapeutics strives to create therapies that cater to the needs of individuals facing these health challenges, ultimately aiming to improve outcomes over time.
America has an Obesity Problem
America’s obesity rate has been rising for years and is reaching a fever pitch in the 2020s. Unfortunately, many of the causes of obesity will not go away any time soon, and most Americans will not take the extra steps necessary to avoid them. Obesity in America is influenced by factors such as eating habits, lack of physical exercise, and environmental conditions. The easy availability of caloric-dense foods from restaurants like McDonalds ((MCD - Free Report) ) and Shake Shack ((SHAK - Free Report) ) plays a significant role in the issue.Meanwhile, even coffee establishments like Starbucks ((SBUX - Free Report) ) have many drinks packed with orders of magnitude of the daily sugar intake one should consume. Finally, societal norms regarding portion sizes and eating habits also impact the increasing obesity rate.
Image Source: NIH
Heart Disease is the Number One Killer
Heart disease, which is mainly caused by an unhealthy diet and physical inactivity, causes more deaths annually than any other disease. In 2021, heart disease was responsible for 13% of all deaths in the United States and was the top cause of death for both genders (according to the World Health Organization (WHO))
GLP-1 Drugs Have Blockbuster Potential
For many Americans, the fix for a rampant obesity problem and other obesity-linked issues like diabetes may be GLP-1 drugs. GLP-1s imitate the functions of a hormone known as glucagon peptide. This hormone helps to manage blood sugar levels and appetite. These medicines are commonly prescribed for treating type 2 diabetes as they enhance insulin production and stomach digestion. Some GLP-1 drugs like Novo Nordisk’s ((NVO - Free Report) ) Ozempic and Eli Lilly’s ((LLY - Free Report) ) have already hit the market, and resulted in massive earnings for each company.
Image Source: Zacks Investment Research
Viking’s Best-in-Breed Weight Loss Drug
In late February, VKTX shares more than doubled in a single session after the company announced positive top-line results for its VK2735 GLP-1 drug. However, Eli Lilly and Novo Nordisk have enjoyed the first-mover advantage. Nevertheless, VKTX may be the most attractive stock for three reasons:
1. Room to Grow: VKTX’s market cap is tiny compared to LLY and NVO.With the GLP-1 market expected to grow to $500 billion in the next few years, even a small capture of the weight loss market could mean big gains for VKTX shares.
2. Effectiveness: In clinical trials, patients taking Ozempic saw similar results to VK2735 patients, but it took them 68 weeks to see those results, compared to 13 weeks for VK2735 patients. Meanwhile, Phase 2 studies have shown that Viking’s drug is about twice as effective as LLY’s.
3. Acquisition Candidate: A large drug maker like Pfizer (PFE) may look to enter the weight loss market by acquiring VKTX. VKTX would likely be bought out at a very high premium if this were to happen.
VKTX’s Bullish Pattern
Finally, VKTX is setting up in a perfect monthly bull flag pattern. Monday, the stock rose 17% as volume more than doubled (a sign of heavy accumulation).
Image Source: TradingView
Bottom Line
Viking Therapeutics has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
What Does Viking Therapeutics Do?
Viking Therapeutics (VKTX) is a company that develops treatments for metabolic and endocrine disorders. VKTX’s focus is on creating medication to address conditions such as steatohepatitis (NASH), a liver disease, as well as obesity and diabetes. Through its expertise in receptor signaling pathways, Viking Therapeutics strives to create therapies that cater to the needs of individuals facing these health challenges, ultimately aiming to improve outcomes over time.
America has an Obesity Problem
America’s obesity rate has been rising for years and is reaching a fever pitch in the 2020s. Unfortunately, many of the causes of obesity will not go away any time soon, and most Americans will not take the extra steps necessary to avoid them. Obesity in America is influenced by factors such as eating habits, lack of physical exercise, and environmental conditions. The easy availability of caloric-dense foods from restaurants like McDonalds ((MCD - Free Report) ) and Shake Shack ((SHAK - Free Report) ) plays a significant role in the issue.Meanwhile, even coffee establishments like Starbucks ((SBUX - Free Report) ) have many drinks packed with orders of magnitude of the daily sugar intake one should consume. Finally, societal norms regarding portion sizes and eating habits also impact the increasing obesity rate.
Image Source: NIH
Heart Disease is the Number One Killer
Heart disease, which is mainly caused by an unhealthy diet and physical inactivity, causes more deaths annually than any other disease. In 2021, heart disease was responsible for 13% of all deaths in the United States and was the top cause of death for both genders (according to the World Health Organization (WHO))
GLP-1 Drugs Have Blockbuster Potential
For many Americans, the fix for a rampant obesity problem and other obesity-linked issues like diabetes may be GLP-1 drugs. GLP-1s imitate the functions of a hormone known as glucagon peptide. This hormone helps to manage blood sugar levels and appetite. These medicines are commonly prescribed for treating type 2 diabetes as they enhance insulin production and stomach digestion. Some GLP-1 drugs like Novo Nordisk’s ((NVO - Free Report) ) Ozempic and Eli Lilly’s ((LLY - Free Report) ) have already hit the market, and resulted in massive earnings for each company.
Image Source: Zacks Investment Research
Viking’s Best-in-Breed Weight Loss Drug
In late February, VKTX shares more than doubled in a single session after the company announced positive top-line results for its VK2735 GLP-1 drug. However, Eli Lilly and Novo Nordisk have enjoyed the first-mover advantage. Nevertheless, VKTX may be the most attractive stock for three reasons:
1. Room to Grow: VKTX’s market cap is tiny compared to LLY and NVO.With the GLP-1 market expected to grow to $500 billion in the next few years, even a small capture of the weight loss market could mean big gains for VKTX shares.
2. Effectiveness: In clinical trials, patients taking Ozempic saw similar results to VK2735 patients, but it took them 68 weeks to see those results, compared to 13 weeks for VK2735 patients. Meanwhile, Phase 2 studies have shown that Viking’s drug is about twice as effective as LLY’s.
3. Acquisition Candidate: A large drug maker like Pfizer (PFE) may look to enter the weight loss market by acquiring VKTX. VKTX would likely be bought out at a very high premium if this were to happen.
VKTX’s Bullish Pattern
Finally, VKTX is setting up in a perfect monthly bull flag pattern. Monday, the stock rose 17% as volume more than doubled (a sign of heavy accumulation).
Image Source: TradingView
Bottom Line
Viking Therapeutics has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.